Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemia
Y. Yin, P. Athanasiadis, L. Karlsen, A. Urban, I. Murali, S. M. Fernandes, A. J. Arribas, A. K. Hilli, K. Tasken, F. Bertoni, A. R. Mato, E. Normant, J. R. Brown, G. E. Tjonnfjord, T. Aittokallio, S. S. Skanland
This study uses ex vivo drug sensitivity testing to identify treatment responses and vulnerabilities in chronic lymphocytic leukemia patients, showing that pan-PI3Ki and combinations with venetoclax can be effective in idelalisib-refractory/intolerant cases.
bioRxiv · Apr 14, 2022 · PreprintCancer Biology